Status:
COMPLETED
Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT)
Lead Sponsor:
Northside Clinic, Australia
Collaborating Sponsors:
Wesley Mission
Conditions:
Major Depressive Episode
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Research into the mechanisms underlying memory impairment in ECT suggests that its development may be prevented by the administration of certain medications at the time of ECT treatment. For example t...
Detailed Description
This study will report on two related trials. In the outpatient trial, patients will be administered adjunctive ketamine at two different doses (0.25mg/kg; 0.5mg/kg), and a placebo (saline), across 3 ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Satisfy DSM-IV-TR criteria for Major Depressive Episode
- 18 years or over
- Does not have a diagnosis of schizophrenia, schizoaffective disorder, rapid cycling bipolar disorder, or current psychotic symptoms
- No known sensitivity to ketamine
- No ECT in the last 3 months
- No drug or alcohol abuse in the last 12 months
- Able to give informed consent
- Score at least 24 on Mini Mental State Examination
Exclusion
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT00680433
Start Date
April 1 2008
End Date
October 1 2012
Last Update
March 29 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wesley Hospital
Sydney, New South Wales, Australia, 2217